Ian Rowe and colleagues have created a model to assess the tradeoff of liver risk reduction vs. CVD risk reduction at different levels of fibrosis and age. The model suggests that for F2 and F3 patients, the cardiovascular profile of a medication may have greater effect on overall morbidity and mortality than the liver profile, even if the drug produces significant liver improvements. The model and its outputs are enlightening, the questions it raises are clinically important. Stephen Harrison shares some recently available data on efruxifermin that suggests a positive effect for compensated cirrhotics, and questions what a drug must do to make sense for earlier stage patients.
TOPICS: rrhosis, Diabetes, Drug Trial, efruxifermin, FGF-21, Fibrosis Level 3, Fibrosis Level 4, NAFLD, NASH, non-invasive liver testing, Obesity, Fibrosis Level 2, STELLAR-4 trial, cardiovascular outcomes, treatment pathways, alcohol consumption
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast